Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022
Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a conference call on March 11, 2022, at 8:30 a.m. ET to discuss its financial results for the full year ended December 31, 2021, along with a business overview. The company utilizes its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop targeted cancer drugs. Key products include prexigebersen, in a Phase 2 study for blood cancers, and prexigebersen-A, which has FDA clearance for a Phase 1 study in solid tumors. An IND application for BP1003 is expected in 2022.
- FDA clearance for prexigebersen-A to begin Phase 1 studies in solid tumors in 2022.
- Ongoing Phase 2 study of prexigebersen for blood cancers, indicating continued clinical development.
- Expected IND filing for BP1003, indicating ongoing innovation in cancer treatment.
- None.
HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 11, 2022 at 8:30 a.m. ET to report financial results for the full year ended December 31, 2021 and to provide a business overview.
To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 5089985. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, has been cleared by the FDA and Phase 1 studies in solid tumors will commence in 2022. The Company’s second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
FAQ
When will Bio-Path Holdings report its financial results?
What is the focus of Bio-Path Holdings' pipeline?
What is prexigebersen and its current status?